Saos-2

Saos-2 cells, originating from bone tissue in an 11-year-old White female osteosarcoma patient subjected to a regimen of radiation therapy (RTG), methotrexate, adriamycin, vincristine, cytoxan, and aramycin-C, exhibit epithelial morphology and display osteoblastic characteristics, allowing for full osteoblastic differentiation. They express receptors for 1,25-dihydroxy vitamin D3 and maintain elevated basal alkaline phosphatase activity. These cells also express the parathyroid hormone (PTH) receptor and respond to PTH treatment by producing cyclic AMP. Remarkably, Saos-2 cells fail to form subcutaneous tumors in immunocompromised mice but, when placed intra-peritoneally in diffusion chambers, give rise to a mineralized matrix, mirroring osteoblastic behavior. With a doubling time of 48 hours, they demonstrate resistance to p53-mediated apoptosis and heightened sensitivity to DNA damage induced by chemotherapeutic agents.

Why choose Saos-2 from AcceGen?

Saos-2 cells from AcceGen boast exceptional viability and quality, cultivated under optimal conditions. They are provided in a sterile state, with rigorous testing confirming the absence of mycoplasma and various viruses, including EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1/2, MLV, and SMRV. These cells undergo continuous daily monitoring to maintain their purity and are authenticated through STR analysis to ensure their identity.